This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 123 studies, archived under the term: "cholinesterase inhibitors"

Click here to filter this large number of results.

Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands

Objectives: Since January 2008 in The Netherlands, two cholinesterase inhibitors, oral galantamine and rivastigmine transdermal patch, are registered as a one-day symptomatic treatment for Alzheimer’s disease. As no head to head study was performed yet, the objective of this study was to describe the daily practice of oral galantamine and rivastigmine transdermal patch in a […]

The long-term efficacy and tolerability of donepezil in patients with vascular dementia

Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD).; Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer’s […]

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease

Background: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer’s disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. Methods: Six hundred and eighty-one deceased patients with a clinical […]

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer’s disease: a study in a real life population

Aim: To record in real life the appreciation of elderly patients, their caregivers and physicians of a once daily formulation of prolonged release of galantamine in the treatment of mild to moderate Alzheimer’s disease.; Methods: A prospective, multicenter, observational study was conducted in 128 elderly patients, treated for 6 months with galantamine, donepezil or rivastigmine.; […]

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study

The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the […]

Cognitive subdomain responses to galantamine in Alzheimer’s disease

We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]

Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep

Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]

Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease

Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer’s disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comparable AD patients relative to the treated groups. Fifteen patients recently diagnosed of […]

Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?

Background/aims: A full comparison of the satisfaction with treatment using the current Alzheimer’s disease (AD) therapies from the perspective of caregivers has not yet been done. The aim of this study was thus to find out the degree of satisfaction with the main available drug treatments in monotherapy for AD from this point of view.; […]

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative

Objectives: To assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride.; Design: Cohort study.; Setting: The 59 recruiting sites for the Alzheimer’s Disease Neuroimaging Initiative (ADNI).; Participants: Outpatients with MCI and AD in ADNI.; Main Outcome Measures: The […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: